Actelion Setback Ahead Of J&J Deal Closure
Executive Summary
A setback for Actelion – and Johnson & Johnson – as it reports mixed Phase III data for the Clostridium difficile treatment candidate cadazolid.
You may also be interested in...
Antibiotic Pipeline Profile: Narrowing The Spectrum Of Drug Activity
Development is most advanced in C. difficile infection, but US FDA's exploration of pathways to expedite single pathogen treatments could spur earlier-stage QIDP projects targeting Staphylococcus and Pseudomonas species.
Clozel's CHF1bn Actelion Spin-Out Idorsia Awaits Janssen Buy-In
Upon completion of Johnson & Johnson's $30bn acquisition of Actelion, Jean-Paul Clozel, the latter's outgoing CEO, aims to build a new European biopharma big-hitter – Idorsia – with the earlier-stage assets Actelion leaves behind. He's hoping that J&J's Janssen will soon opt in to rights to its lead candidate. Idorsia is preparing to launch onto the Swiss Stock Exchange with CHF1bn in cash at inception.
Tetraphase Bets On I.V. Eravacycline Rerun As Antibiotic Market Influx Looms
Tetraphase has been keeping its head down since a 2015 Phase III trial failure for its lead antibiotic drug eravacycline sliced around $1.3bn from the company's market cap – but 2017 will be a turnaround year, says CEO Guy Macdonald.